阿立哌唑与奎硫平治疗女性首发精神分裂症的随机双盲双模拟平行对照研究

・学术交流・阿立哌唑与奎硫平治疗女性首发精神分裂症的随机、

双盲、双模拟平行对照研究

韦盛中

【摘要】　目的　比较阿立哌唑与奎硫平治疗女性首发精神分裂症的疗效和安全性。方法　采用随

机、双盲、双模拟平行对照的方法,对符合CCMD-3精神分裂症诊断标准的女性首发精神分裂症患者,

随机使用阿立哌唑和奎硫平治疗8周。采用阳性症状与阴性症状量表(PANSS)、临床总体印象量表

(CGI)评定疗效,采用副反应量表(TESS)评定副反应。结果　101例女性首发精神分裂症患者完成了

研究,阿立哌唑组50例,奎硫平组51例。治疗8周后,阿立哌唑组显效率为66.0%,有效率为92.0%;

奎硫平组显效率为64.7%,有效率为92.2%。两组疗效在统计学上无显著性差异(P>0.05)。阿立哌

唑组总副反应发生率为34.00%,奎硫平组总副反应发生率35.29%,两组间比较在统计学上无显性著

差异(P>0.05)。阿立哌唑组和奎硫平组均出现较多的副反应是嗜睡(16.00%∶19.61%)、头昏和昏

厥(12%∶13.73%),但两组间比较在统计学上无显性著差异(P>0.05)。阿立哌唑组恶心呕吐、头痛

的发生率比奎硫平组多(14.00%∶1.96%,P<0.05;18.00%∶1.96%,P<0.01),奎硫平组口干、

食欲减退或厌食比阿立哌唑组多(均为15.69%∶2.00%,P<0.05)。两组锥体外系反应不明显,较少

引起体重增加和月经紊乱,没有发现溢乳现象。结论　阿立哌唑和奎硫平对女性首发精神分裂症疗效

相当,副反应轻,而且副反应表现有异同。两种药物均为疗效好、安全性高,对体重和月经影响较小、无

溢乳的抗精神病药,有利于提高女性精神分裂症患者服药的依从性。

【关键词】　阿立哌唑;　奎硫平;　女性;　精神分裂症

A randomized,double blind,double dummy parallel controlled study in the fem ale f irst-

ondet schizophrenia treated with aripiprazole and quetiapine　W EI S heng2z hong1　The

Fi f th People’s Hos pital of N anning,N anning530001,China

【Abstract】　Objective　To compare efficacy and safety of aripiprazole and quetiapine in the treat2

ment of female first-ondet schizophrenia.Methods　The randomized,Double blind,double dummy par2

allel controlled was designed for this study.All the cases were diagnosed as schizophrenia in accordance

with the CCMD-3diagnosis standard and randomized into two group s which were treated with aripi2

prazole or quetiapine for8weeks.The Positive and Negative Syndrome Scale(PANSS),Clinical G lobal

Impression(CGI)and Treatment Emergent Side effect Scale(TESS)were used to evaluate efficacy and

adverse effects respectively before and at the ends of2,4,8weeks treatment.R esults　101adult female

first-onset schizophrenia patients were recruited in this study.The significant efficacy rates of aripi2

prazole was66.0%and the efficacy rate was92%after8weeks and was64.7%and92.2%in quetiapine

group.There was no significant difference between the two group s(P>0.05).The incidence rate of

adverse effect was34.00%in aripiprazole group and35.29%in quetiapine group,without any signifi2

cant difference(P>0.05).The adverse effect either in aripiprazole group or in quetiapine group was

drowsiness(16.00%∶19.61%),dizziness and faint(12%∶13.73%).There was no significant differ2

ence between the two groups(P>0.05).The rate of nausea and vomiting,headache in aripiprazole

group was higher than that in quetiapine group(14.00%∶1.96%P<0.05,18.00%∶1.96%P<

0.01).The rate of dry mouth,decrease of appetite or anorexia in quetiapine group was higher than that in

aripiprazole group(15.69%∶2.00%P<0.05,15.69%∶2.00%P<0.05).Both drugs showed low

extrapyramidal symptoms,less endocrine change,less weight gain and has not found amenorrhea galac2

torrhea syndrome during treatment.Conclusions　The results suggest that aripiprazole is as effective as

quetiapine for the treatment of female first-onset schizophrenia and fewer side effects in them.They

both are effective and safe antipsychotic drugs in treatment of female first-onset sihizophrenia.They are

beneficial to improve the therapeutic compliance of female first-onset schizophrenia patients.

【K ey w ords】　Aripiprazole;　Quetiapine;　Female;　Schizophrenia

中图分类号:R749.3 文献标识码:A 文章编号:1009-6574(2006)03-0194-04

阿立哌唑(Aripiprazole)是由美国百时美-施贵 作者单位:530001广西壮族自治区南宁市第五人民医院宝公司和日本大冢公司联合开发的非典型抗精神病药,于2002年11月15日由美国FDA批准上市,国产阿立哌唑(博思清)于2004年11月在国内开始使